Palisade Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PALI | CANTA.ST | DMAC | PTN | PMRA.F | ENTX | |
|---|---|---|---|---|---|---|
| Market cap | 217.84M | 475.36M | 580.78M | 10.72M | 1.17B | 540.90M |
| P/E (TTM) | 2.1 | 2.5 | — | — | 17.3 | — |
| Forward P/E | -4.4 | -1.8 | -14.4 | -3.2 | — | -5.7 |
| Price/book | 1.8 | 1.6 | 15.1 | 1.6 | 5.0 | 21.2 |
| Dividend yield | — | — | — | — | 1.54% | — |
| 1-year change | −26.79% | −48.13% | +50.38% | −19.69% | −11.53% | +0.33% |
| Today | +1.63% | −2.09% | +7.70% | +15.33% | +6.01% | +1.97% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PALI news ›Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor
Palisade Bio earns a Buy rating as PALI-2108 advances in ulcerative colitis. Click here to read my most recent analysis of PALI stock. - I initiate Palisade Bio with a "Buy" rating, driven by its differentiated oral PDE4 inhibitor prodrug…
Head to Head Comparison: Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI)
Posted by Danessa Lincoln on Oct 31st, 2026 Indivior (NASDAQ:INDV – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies…
Reviewing Palisade Bio (NASDAQ:PALI) and GSK (NYSE:GSK)
Posted by Mitch Edgeman on Oct 31st, 2026 Palisade Bio (NASDAQ:PALI – Get Free Report) and GSK (NYSE:GSK – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the…
Theravance Biopharma (NASDAQ:TBPH) vs. Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast
Posted by Sarita Garza on Oct 31st, 2026 Theravance Biopharma (NASDAQ:TBPH – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the…
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
RTX Reports Q3 2026 Results Palisade reports mean intestinal concentrations of active PALI-0008 higher than peak plasma levels and plasma exposure above an estimated in-vitro PDE4 inhibition threshold for 24 hours at 30 mg once daily,…
HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target
TradingView HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target HC Wainwright & Co. reiterated their Buy rating on Palisade Bio's stock with a price target of $7.00. The price target implies an upside
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Palisade Bio (Nasdaq: PALI) presented early clinical and mechanistic PALI-2108 findings supporting its ongoing Phase 2 ulcerative colitis and Crohn’s disease development. PALI-2108 is an investigational oral prodrug activated in the…
Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)
Posted by Michael Walen on Oct 24th, 2026 Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast…
Palisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to “Sell”
Posted by Mitch Edgeman on Oct 18th, 2026 Wall Street Zen lowered shares of Palisade Bio (NASDAQ:PALI – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports. View Our…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com6
- seekingalpha.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.